Back to Search
Start Over
421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
- Publication Year :
- 2020
- Publisher :
- BMJ Publishing Group, 2020.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 8
- Issue :
- Suppl 3
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.3a2e10fe643758a8db510b6c2d64c
- Document Type :
- article
- Full Text :
- https://doi.org/10.1136/jitc-2020-SITC2020.0421